iQue Forecyt® software

In this application note, Sartorius highlights the joint power of the Intellicyte iQue® Screener PLUS platform and the ForeCyt® Software to provide actionable insights, driving faster decision-making in the development of cell therapies.

In this application note, Sartorius illustrates how the Intellicyt® iQue Screener PLUS VBR high-throughput flow cytometer and the integrated ForeCyt® software package can be used together as a powerful method for optimizing cell manufacturing protocols. These tools can be easily applied to the profiling of biologics and drugs where the monitoring of T cell memory subsets is required.

The blockbuster success of antibody-based therapeutics for autoimmune diseases, inflammatory diseases and immunooncology accelerated the high stakes monoclonal antibody (mAb) development race. The market for therapeutic uses of mAbs was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024. In addition, mAb research is underway for therapies to treat neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, as well as antibody/drug conjugates (ADC)— mAbs weaponized with radio-isotopes or cytotoxic agents for specific delivery to a cancer cell target.

Antibody engineering is critical to development of new therapies in many fields such as oncology, where monoclonal antibodies are currently the most widely used immunotherapy for cancer. Screening hybridoma libraries for antibodies that bind to cell surface antigens is a time and resource intensive process. The current screening workflow often involves several individual testing steps, including different biochemical tests that test for binding, specificity, followed by cell based assays. In addition to being costly and laborious, purified protein assays such as ELISA that utilize denatured antigens can generate false negatives - potential missed hits that would have bound to antigens in their native conformation. IntelliCyt has developed a “mix-and-measure” intact cell assay for primary screening that simultaneously assesses antigen binding and cross-reactivity.

This poster demonstrates the application of Intellicyt's iQue Screener PLUS and ForeCyt Software for the reliable performance of high-throughput antibody dependent cell-mediated cytotoxicity assays.

Antibody-based therapeutics are the fastest growing and most successful therapeutic modality for treating diseases such as cancer, cardiovascular disease, autoimmune disorders and infectious disease.This whitepaper describes how the iQue Screener is used to perform multiplexed screens for antibody binding to either cell surface or to circulating target antigens. The whitepaper also discusses the use of the same platform to carry out high content assays to evaluate the effects of lead candidates in multiplexed cell based and secreted protein assays.

Comprehensive digital guide to high-throughput screening (HTS) by cytometry, featuring assays, application data, and more

Vanderbilt researchers use high-throughput data collection, analysis, and visualization to help understand synergy in therapeutic antibody cocktails

Watch this on-demand webinar to learn about the applications for cell-based therapies and biologics using advanced high-throughput flow cytometry

SAIL conducts research into the use of AI in Sartorius platform solutions for the biopharmaceutical industry

Join this expert SelectScience webinar to find out how to achieve detailed T cell characterization data

Watch this on-demand webinar to learn how solutions from Sartorius are designed to increase the throughput of nanobody screening and discovery

The latest solution offered in Sartorius’ cellular analysis portfolio is designed to fully automate processing and analysis for flow cytometry workflows

Join this webinar to learn more about the new generation of therapeutic antibodies and find out how solutions from Sartorius can be used to accelerate their identification

From cancer biosimilars to AI PCR & the technologies making gene therapy a reality, discover the top trending content that caught the attention of SelectScience readers in April 2019

Learn how you can accelerate your decision-making for suspension cell analysis